BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26083988)

  • 1. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes C; Martins C; João I; Pereira H
    BMC Res Notes; 2014 Dec; 7():891. PubMed ID: 25491419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin.
    Vijenthira A; Le Gal G; Castellucci LA; Carrier M
    Thromb Res; 2014 Sep; 134(3):584-6. PubMed ID: 25037497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction Score for Anticoagulation Control Quality Among Older Adults.
    Lin KJ; Singer DE; Glynn RJ; Blackley S; Zhou L; Liu J; Dube G; Oertel LB; Schneeweiss S
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
    Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
    Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.
    Barrios V; Escobar C; Prieto L; Osorio G; Polo J; Lobos JM; Vargas D; García N
    Rev Esp Cardiol (Engl Ed); 2015 Sep; 68(9):769-76. PubMed ID: 26169326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mkomanga WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Tadesse TA; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.
    Lafarge L; Khayi F; Bel-Kamel A; Charhon N; Sarfati L; Falquet B; Ducher M; Bourguignon L
    Drugs Aging; 2018 Jun; 35(6):569-574. PubMed ID: 29882202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
    Barco S; Granziera S; Coppens M; Douxfils J; Nijkeuter M; Riva N; Vanassche T; Zhang G; Lin M; Kamphuisen PW; Cohen AT; Beyer-Westendorf J
    Thromb Haemost; 2019 Apr; 119(4):675-684. PubMed ID: 30731492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.